Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TGD001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TargED Biopharmaceuticals Doses First Participant in Phase 1 Trial Of TGD001
Details : TGD001 is a groundbreaking thrombolytic designed to break down clots of all sizes and compositions, being investigated for acute ischemic stroke and TTP.
Product Name : TGD001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : TGD001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Microlyse
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Andera Partners
Deal Size : $43.7 million
Deal Type : Series A Financing
Details : Funds will accelerate development of first-in-class targeted thrombolytic treatment into clinical development. TargED’s lead product, Microlyse, is a first-in-class proprietary clot-busting compound which binds to a protein present in all forms of thro...
Product Name : Microlyse
Product Type : Protein
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : Microlyse
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Andera Partners
Deal Size : $43.7 million
Deal Type : Series A Financing
Reset All
